Overview

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Status:
Enrolling by invitation
Trial end date:
2022-10-10
Target enrollment:
Participant gender:
Summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Japanese Participants with Chronic or Episodic Migraine
Phase:
Phase 3
Details
Lead Sponsor:
Allergan